Clinical drug development using dynamic biomarkers to enable personalized health care in Chronic Obstructive Pulmonary Disease

Research output: Contribution to journalReviewResearchpeer-review

  • Asger R Bihlet
  • Morten A Karsdal
  • Anne-Christine Bay-Jensen
  • Simon Read
  • Jacob Hull Kristensen
  • Jannie Marie Bülow Sand
  • Diana Julie Leeming
  • Jeppe Ragnar Andersen
  • Lange, Peter
  • Jørgen Vestbo

Despite massive investments in development of novel treatments for heterogeneous diseases such as Chronic Obstructive Pulmonary Disease (COPD), the resources spent have only benefitted a fraction of the population treated. Personalized Health Care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. In this review, we discuss past successes and failures in drug development and biomarker research in COPD. We describe research in COPD phenotypes, and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression. We review the role of extra-cellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling which may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacological intervention are discussed.

Original languageEnglish
Issue number1
Pages (from-to)16-23
Number of pages8
Publication statusPublished - Jul 2015

ID: 135784413